drugset
drugset / Trial / NCT06138691

KET-RO Plus RO DBT for Treatment Resistant Depression

NCT06138691 ↗

Phase 1 Completed 16 enrolled Washington University School of Medicine
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD). In addition, this study will develop and utilize innovative methodological approaches to demonstrate the feasibility of precision medicine with this type of therapy.

Timeline

Start
2023-10-04
Primary completion
2025-01-11
Completion
2025-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous

Indications

No indication recorded.